GRFS: Grifols, S.A. Growth-Adjusted Market Cap to Net Income
The growth-adjusted P/E ratio demonstrates the market resilience of Grifols, S.A., with the metric reaching 0.33. This trend is based on a qualified medical staff with global prospects and the high profitability of critical biopharmaceuticals. Business efficiency is further enhanced by the implementation of robotic fractionation lines, which completely eliminate manual labor in sterile production zones.
Metric breakdowns and analytics for Grifols, S.A. (GRFS)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
GRFS - Net Profit|Company Profit Forecast Grifols, S.A.|GRFS - P/E Multiple|Price to Expected Earnings Ratio Grifols Biemat|GRFS - Price/Earnings to Growth Ratio|Company Value to EBITDA Grifols Group|GRFS - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Grifols|GRFS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months grifols.com|GRFS - Net earnings per share growth this year|Expected earnings per share trend next year Grifols, S.A.
General company analysis:GRFS - Grifols SA
For the plasma-derived medicines market leader Grifols, S.A. (GRFS), which benefits from colossal barriers to entry, the relationship between the company's valuation and its growth rate serves as a tool for verifying the asset's fair value. This metric compares the P/E ratio with annual earnings growth: a value below one indicates that the business is undervalued, which, when analyzed alongside the debt load, confirms capital stability and investment potential.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple ADPT|PEG Multiple Celldex Corp|Price/Earnings to Growth Ratio Aurinia Pharmaceuticals (AUPH)|biocryst.com - Growth-Adjusted P/E Ratio|PEG Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Price to Earnings Adjusted for Growth Rate|Pharvaris Corp - PEG Multiple|Price to Net Income Growth Ratio AbCellera Biologics (ABCL)|Tourmaline Bio, Inc. (TRML) - Price/Earnings to Growth Ratio|precigen.com - Growth-Adjusted Payback Ratio|PHAR (Pharming Group) - PEG Multiple|Nektar Therapeutics Inc (NKTR) - Growth-Adjusted Market Cap to Net Income|PEG Multiple UPB|ZBIO: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Immunome, Inc. IMNM|gossamerbio.com (GOSS) - Price to Earnings Adjusted for Growth Rate|KALV - Price/Earnings to Growth Ratio|SEPN: Price/Earnings to Growth Ratio|Pieris Pharmaceuticals Inc (PVLA) - Price/Earnings to Growth Ratio|SVRA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RIGL|ANAB: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Astria Therapeutics, Inc. (ATXS)|Growth-Adjusted Market Cap to Net Income enGene Holdings Inc|RAPT Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Aerovate Therapeutics, Inc. (JBIO)|Aclaris Therapeutics - PEG Multiple|KYTX - PEG Multiple|TLSA (Tiziana Life Sciences Ltd) - Price/Earnings to Growth Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (Ventyx Bio) - PEG Multiple|THTX - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio Avalo Therapeutics, Inc (AVTX)|ELDN (eledon.com) - Growth-Adjusted Payback Ratio|PEG Multiple AGEN (Agenus Inc.)|CLYM (Climb Bio Inc.) - Market Cap to Earnings and Growth Ratio|ZURA - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income aTyr Pharmaceuticals ATYR|adagene.com (ADAG) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio IMA (Ikena Oncology)|STTK (Shattuck Labs Inc) - PEG Multiple|EQ: Growth-Adjusted Payback Ratio|PEG Multiple CNTB|PEG Multiple immunic-therapeutics.com (IMUX)|Price/Earnings to Growth Ratio Atara Bio ATRA|Growth-Adjusted Payback Ratio IFRX|XFOR - Price/Earnings to Growth Ratio|Adicet Bio (ACET) - Price/Earnings to Growth Multiple|CELU: PEG Multiple|INmune Bio Corporation (INMB) - PEG Multiple|Price/Earnings to Growth Multiple BRNS|KZR: Growth-Adjusted Payback Ratio|PEG Multiple SABS|Growth-Adjusted Market Cap to Net Income Akari Therapeutics PLC|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Price/Earnings to Growth Multiple|GOVX - Price/Earnings to Growth Ratio|edesabiotech.com (EDSA) - Price/Earnings to Growth Multiple|IBIO (iBio) - Price/Earnings to Growth Multiple|Carisma Therapeutics Inc. (CARM) - PEG Multiple|Price/Earnings to Growth Ratio XTL Biopharmaceuticals, Ltd.|Growth-Adjusted P/E Ratio BOLT (Bolt Bio)|PEG Multiple HCWB|APVO - Price to Earnings Adjusted for Growth Rate|PEG Multiple AIM (AIM ImmunoTech)|Price to Net Income Growth Ratio Aditxt Inc.|GRI - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio XRTX (XORTX Corp)|HIND: PEG Multiple|REVB - Growth-Adjusted Market Cap to Net Income|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|Scinai Immunotherapeutics Ltd - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Allakos ALLK|HOOKIPA Pharma, Inc. - Price/Earnings to Growth Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics Inc ITOS|OCEA (Ocean Bio) - Price/Earnings to Growth Multiple|TC BioPharm Ltd - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Third Harmonic Bio
